Abstract | AIMS: MAIN METHODS: We examined the hypoglycaemic mechanism of catalpol in db/db mice and C2C12 cells. db/db mice were treated with catalpol (200 mg/kg) for 8 consecutive weeks. Serum analysis, skeletal muscle performance and histology, and gene and protein expression were performed. In vitro glucose uptake, gene and protein expression were determined, and small interfering RNA was used to identify the underlying hypoglycaemic mechanism of catalpol. KEY FINDINGS: SIGNIFICANCE:
|
Authors | Dengqiu Xu, Lu Wang, Zhenzhou Jiang, Guolin Zhao, Hozeifa M Hassan, Lixin Sun, Sisi Fan, Zhixing Zhou, Luyong Zhang, Tao Wang |
Journal | Life sciences
(Life Sci)
Vol. 209
Pg. 313-323
(Sep 15 2018)
ISSN: 1879-0631 [Electronic] Netherlands |
PMID | 30118770
(Publication Type: Journal Article)
|
Copyright | Copyright © 2018 Elsevier Inc. All rights reserved. |
Chemical References |
- Blood Glucose
- Hypoglycemic Agents
- Iridoid Glucosides
- MyoD Protein
- MyoD1 myogenic differentiation protein
- Myog protein, mouse
- Myogenin
- catalpol
|
Topics |
- Animals
- Blood Glucose
(metabolism)
- Cell Differentiation
(drug effects)
- Diabetes Mellitus, Experimental
(drug therapy, metabolism, pathology)
- Diabetes Mellitus, Type 2
(drug therapy, metabolism, pathology)
- Hypoglycemic Agents
(pharmacology)
- Insulin Resistance
- Iridoid Glucosides
(pharmacology)
- Male
- Mice
- Mice, Inbred C57BL
- Muscle Development
(drug effects)
- Muscle, Skeletal
(drug effects, physiology)
- MyoD Protein
(metabolism)
- Myogenin
(metabolism)
|